Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib

Journal of Clinical Oncology

Volumn 24, Issue 24, 2006, Pages 4028-4029

  Hyun, Jung Kim ^a   Chul, Won Jung ^a   Kim, Kihyun ^a   Jin, Seok Ahn ^a   Won, Seog Kim ^a   Park, Kwan ^a   Young, Hye Ko ^a   Won, Ki Kang ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DEXAMETHASONE; HYDROCORTISONE; IMATINIB; INTERFERON; MANNITOL; METHOTREXATE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ANASTOMOSIS; ARTICLE; BONE MARROW BIOPSY; BRAIN DECOMPRESSION; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CRANIOTOMY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTRACRANIAL HYPERTENSION; LABORATORY TEST; LUMBAR PUNCTURE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BLAST CELL CRISIS; CEREBELLUM; DRUG ADMINISTRATION; FATALITY; INTRASPINAL DRUG ADMINISTRATION; MYELOID LEUKEMIA; PATHOLOGY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CEREBELLUM; DRUG ADMINISTRATION SCHEDULE; FATAL OUTCOME; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INJECTIONS, SPINAL; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; PIPERAZINES; PYRIMIDINES;

EID: 33748450738     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.5608     Document Type: Article

References (10)

1. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003
2. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
3. Peggs K, Mackinnon S: Imatinib mesylate: The new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348:1048-1050, 2003
4. Bornhauser M, Jenke A, Freiberg-Richter J, et al: CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 83:401-402, 2004
5. Leis JF, Stepan DE, Curtin PT, et al: Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 45:695-698, 2004
6. Takayama N, Sato N, O'Brien SG, et al: Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119:106-108, 2002
7. Dai H, Marbach P, Lemaire M, et al: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085-1092, 2003
8. Wolff NC, Richardson JA, Egorin M, et al: The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101:5010-5013, 2003
9. Bujassoum S, Rifkind J, Lipton JH: Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 45:401-403, 2004
10. Petzer AL, Gunsilius E, Hayes M, et al: Low concentrations of STI571 in the cerebrospinal fluid: A case report. Br J Haematol 117:623-625, 2002